Literature DB >> 7775445

The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor.

S M Zurawski1, P Chomarat, O Djossou, C Bidaud, A N McKenzie, P Miossec, J Banchereau, G Zurawski.   

Abstract

Interleukin (IL)-13 elicits a subset of the biological activities of the related IL-4. The basis of this functional similarity is that their specific cell-surface receptors (called IL-13R and IL-4R) are distinct, yet are complex and share a common subunit(s). The IL-4R primary binding subunit (called IL-4R alpha) does not by itself bind IL-13. We show that the ability of IL-13 to partially compete for IL-4 binding to some human cell types depended on co-expression of IL-4R and IL-13R. However, IL-13 binding was always associated with IL-4 binding. Hyper-expression of IL-4R alpha on cells expressing both IL-4R and IL-13R decreased their binding affinity for IL-4, abrogated the ability of IL-13 to compete for IL-4 binding, and yet had no effect on IL-13R properties. Anti-human IL-4R alpha monoclonal antibodies which blocked the biological function and binding of IL-4 also blocked the function and binding of IL-13. These data show that IL-4R alpha is a secondary component of IL-13R.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775445     DOI: 10.1074/jbc.270.23.13869

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Selective induction of cell adhesion molecules by proinflammatory mediators in human cardiac microvascular endothelial cells in culture.

Authors:  Jun Yan; Adrian D Nunn; Regi Thomas
Journal:  Int J Clin Exp Med       Date:  2010-10-23

2.  Low expression of the interleukin (IL)-4 receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells.

Authors:  Cuixia Tian; Grace K Kron; Kevin M Dischert; James N Higginbotham; James E Crowe
Journal:  Immunology       Date:  2006-06-08       Impact factor: 7.397

3.  Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha.

Authors:  M G Malabarba; H Rui; H H Deutsch; J Chung; F S Kalthoff; W L Farrar; R A Kirken
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

Review 4.  Immunity to gastrointestinal nematode infections.

Authors:  D Sorobetea; M Svensson-Frej; R Grencis
Journal:  Mucosal Immunol       Date:  2018-01-03       Impact factor: 7.313

Review 5.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

Review 6.  Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling.

Authors:  Yutong Zhao; Viswanathan Natarajan
Journal:  Cell Signal       Date:  2008-10-26       Impact factor: 4.315

7.  Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1.

Authors:  B Schnyder; H Lahm; G Woerly; N Odartchenko; B Ryffel; B D Car
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

8.  Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells.

Authors:  Yutong Zhao; Donghong He; Jing Zhao; Lixin Wang; Alan R Leff; Ernst Wm Spannhake; Steve Georas; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2007-02-06       Impact factor: 5.157

9.  Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.

Authors:  H H Jabara; S R Brodeur; R S Geha
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

10.  IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.

Authors:  P P C Souza; A B Brechter; R I Reis; C A S Costa; P Lundberg; U H Lerner
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.